Patent: 8,008,003
✉ Email this page to a colleague
Summary for Patent: 8,008,003
| Title: | Gene expression profiling of EGFR positive cancer |
| Abstract: | The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. |
| Inventor(s): | Baker; Joffre B. (Montara, CA), Cronin; Maureen T. (Los Altos, CA), Shak; Steve (Hillsborough, CA), Baselga; Jose (Barcelona, ES) |
| Assignee: | Genomic Health, Inc. (Redwood City, CA) |
| Application Number: | 10/714,195 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,008,003
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2022-11-15 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2022-11-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
